InterMune, Inc. CEO: Bittersweet Ending To A Biotech Comeback Story

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

InterMune Inc.’s comeback story — from a drug rejection by the FDA to an $8.3 billion buyout offer Sunday from drug giant Roche — is mixed for Dan Welch. After shedding some of the Brisbane company’s (NASDAQ: ITMN) key assets, focusing resources on a huge, new study and convincing investors to pony up more cash to support the effort, Welch and much of his leadership team may be out of jobs in a few months.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news